ASCVD Risk Scores

What are the cardiovascular outcomes of tirzepatide in real‑world observational studies beyond the first two years of treatment?

Real‑world observational studies of to date are short (median follow‑up well under two years) and heterogeneous, so there is effectively no robust real‑world evidence demonstrating cardiovascular outc...